Ottawa, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The global GMP peptides market size is calculated at USD 1.41 billion in 2025 and is expected to reach around USD 2.9 billion by 2034, growing at a CAGR of ...

Peptides and oligonucleotides are transforming modern medicine. Peptide-based drugs have become the fastest-growing segment of chemically synthesized therapeutics, with over 80 approved worldwide, ...

STAAD, Switzerland--(BUSINESS WIRE)--Biosynth, a supplier of critical materials to the life science industry, is pleased to announce the acquisition of Pepceuticals, a UK producer of synthetic ...

With pharma increasingly focusing on biologics and moving peptide drugs through their pipelines into late-stage development, and the research community focusing significant resources on vaccines and ...

The bottom line is that the GMP peptide industry shows great potential for growth, but how many of the products currently moving through and coming into the pipeline will make it to the market, and on ...

MATTHEWS, N.C. & NORTH AUGUSTA, S.C.--(BUSINESS WIRE)--CEM Corporation and AmbioPharm, Inc. are excited to announce the formation of a partnership for production of GMP peptides for the global market.

Today, Pepscan announced that its GMP production capacity has doubled. Pepscan is an all-in-one partner in peptides, building on 25 years of experience in advancing and applying peptide expertise to ...

The bacterial second messenger cyclic diguanylate (c-di-GMP) regulates a wide range of cellular functions from biofilm formation to growth and survival. Targeting a second-messenger network is ...

Biosynth, is pleased to announce the acquisition of Pepceuticals, a UK producer of synthetic peptides with multi-kilogram GMP facilities and fill-finish capabilities designed to support customers from ...